Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

(2019) Marie Scully et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of thrombotic thrombocytopenic purpura

(2017) P. Coppo   TRANSFUSION CLINIQUE ET BIOLOGIQUE

Thrombotic thrombocytopenic purpura

(2017) Johanna A. Kremer Hovinga et al.   Nature Reviews Disease Primers

Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review

(2016) Bashiar Thejeel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

(2016) Flora Peyvandi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura

(2015) Bowie Han et al.   AMERICAN JOURNAL OF HEMATOLOGY

How I treat refractory thrombotic thrombocytopenic purpura

(2015) Farzana A. Sayani et al.   BLOOD

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends

(2015) P. J. Lenting et al.   BLOOD

von Willebrand factor, Jedi knight of the bloodstream

(2014) T. A. Springer   BLOOD

Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center

(2014) Y. Benhamou et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura

(2013) C. C. Deford et al.   BLOOD

Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes

(2013) T. Falter et al.   Hamostaseologie

Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features

(2013) Jessica A. Reese et al.   PEDIATRIC BLOOD & CANCER

von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

(2012) Gui-Ping Luo et al.   ACTA HAEMATOLOGICA

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

(2012) Marie Scully et al.   BRITISH JOURNAL OF HAEMATOLOGY

Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics

(2012) Bernd Meibohm et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

(2012) Paul Coppo et al.   PRESSE MEDICALE

The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura

(2012) Josefin-Beate Holz   TRANSFUSION AND APHERESIS SCIENCE

Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor

(2011) J. T. B. Crawley et al.   BLOOD

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

(2011) H. Ulrichts et al.   BLOOD

Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab

(2010) Jens Marcus Chemnitz et al.   ANNALS OF HEMATOLOGY

Pathophysiology of thrombotic thrombocytopenic purpura

(2010) Han-Mou Tsai   INTERNATIONAL JOURNAL OF HEMATOLOGY

Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo

(2008) C. J. van Schooten et al.   BLOOD

Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features

(2008) Marie Scully et al.   BRITISH JOURNAL OF HAEMATOLOGY